Natalie A Schwehr1, Karen M Kuntz1, Mary Butler1, Eva A Enns1, Nathan D Shippee1, Elaine Kingwell2, Helen Tremlett2, Adam F Carpenter3. 1. Division of Health Policy & Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 2. Division of Neurology, Faculty of Medicine, The University of British Columbia and Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada. 3. Department of Neurology, Medical School, University of Minnesota and Brain Sciences Center, Veterans Affairs Medical Center, Minneapolis, MN, USA.
Abstract
BACKGROUND: Relapsing-onset multiple sclerosis (MS) typically starts in early- to mid-adulthood, yet the trajectory of disease activity over the subsequent lifetime remains poorly defined. Previous studies have not quantified the age-specific portion of decreases in annualized relapse rates (ARR). OBJECTIVE: The aim of this article is to determine, under a range of disease-related assumptions, the age-specific component of decreases in ARR over time among adults with relapsing-onset MS. METHODS: We used a simulation modeling approach to examine a range of assumptions about changes in ARR due to age versus disability status. Scenarios included variations in initial ARR and rate of worsening on the Expanded Disability Status Scale. Model parameters were developed through analysis of MS patients in British Columbia, Canada, and literature review. RESULTS: We found a substantial age-specific decrease in ARR in all simulated scenarios, independent of disability worsening. Under a range of clinically plausible assumptions, 88%-97% of the decrease was attributed to age and 3%-13% to disability. The age-specific decrease ranged from 22% to 37% per 5 years for a wide range of initial ARR (0.33-1.0). CONCLUSION: Decreases in ARR were due mostly to age rather than disability status. To facilitate informed decision making in MS, it is important to quantify the dynamic relationship between relapses and age.
BACKGROUND: Relapsing-onset multiple sclerosis (MS) typically starts in early- to mid-adulthood, yet the trajectory of disease activity over the subsequent lifetime remains poorly defined. Previous studies have not quantified the age-specific portion of decreases in annualized relapse rates (ARR). OBJECTIVE: The aim of this article is to determine, under a range of disease-related assumptions, the age-specific component of decreases in ARR over time among adults with relapsing-onset MS. METHODS: We used a simulation modeling approach to examine a range of assumptions about changes in ARR due to age versus disability status. Scenarios included variations in initial ARR and rate of worsening on the Expanded Disability Status Scale. Model parameters were developed through analysis of MSpatients in British Columbia, Canada, and literature review. RESULTS: We found a substantial age-specific decrease in ARR in all simulated scenarios, independent of disability worsening. Under a range of clinically plausible assumptions, 88%-97% of the decrease was attributed to age and 3%-13% to disability. The age-specific decrease ranged from 22% to 37% per 5 years for a wide range of initial ARR (0.33-1.0). CONCLUSION: Decreases in ARR were due mostly to age rather than disability status. To facilitate informed decision making in MS, it is important to quantify the dynamic relationship between relapses and age.
Entities:
Keywords:
Multiple sclerosis; aging; decision support techniques; deprescriptions; epidemiology; relapsing/remitting
Authors: E Kingwell; M van der Kop; Y Zhao; A Shirani; F Zhu; J Oger; H Tremlett Journal: J Neurol Neurosurg Psychiatry Date: 2011-08-23 Impact factor: 10.154
Authors: Seidu Inusah; Maria P Sormani; Stacey S Cofield; Inmaculada B Aban; Solomon K Musani; Vinodh Srinivasasainagendra; Gary R Cutter Journal: Mult Scler Date: 2010-09-01 Impact factor: 6.312
Authors: Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers Journal: Neurology Date: 2013-07-09 Impact factor: 9.910
Authors: Simon M Steinvorth; Christian Röver; Simon Schneider; Richard Nicholas; Sebastian Straube; Tim Friede Journal: Mult Scler Date: 2013-03-07 Impact factor: 6.312
Authors: Peter Rieckmann; Diego Centonze; Irina Elovaara; Gavin Giovannoni; Eva Havrdová; Jurg Kesselring; Gisela Kobelt; Dawn Langdon; Sarah A Morrow; Celia Oreja-Guevara; Sven Schippling; Christoph Thalheim; Heidi Thompson; Patrick Vermersch; Karen Aston; Birgit Bauer; Christy Demory; Maria Paz Giambastiani; Jana Hlavacova; Jocelyne Nouvet-Gire; George Pepper; Maija Pontaga; Emma Rogan; Chrystal Rogalski; Pieter van Galen; Ali-Frédéric Ben-Amor Journal: Mult Scler Relat Disord Date: 2017-11-21 Impact factor: 4.339
Authors: Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca Journal: Neurology Date: 2019-02-15 Impact factor: 9.910
Authors: Natalie A Schwehr; Karen M Kuntz; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter; Mary Butler Journal: Drugs Aging Date: 2020-03 Impact factor: 3.923
Authors: S Grahl; M Bussas; B Wiestler; P Eichinger; C Gaser; J Kirschke; C Zimmer; A Berthele; B Hemmer; M Mühlau Journal: Neurotherapeutics Date: 2021-09-24 Impact factor: 7.620